Skye Bioscience, Inc. - Common Stock, par value $0.001 (SKYE)

CUSIP: 83086J200

Q4 2024 13F Holders as of 31 Dec 2024

Holder snapshot 7 signals
Share change
-509,607
Put/Call ratio
0%
SEC-reported price per share
$2.83
Number of holders
70
Value change
-$3,219,919
Number of buys
37
Open additional details 1 more signal available
Number of sells
21
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
37,329,162

Security key

83086J200

Report period

Q4 2024

Institutions

70

Top holders

10

Ownership snapshot

Top reported holders of SKYE - Skye Bioscience, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Versant Ventures III, LLC
Disclosed value leader
5AM Venture Management, LLC
Comparable rows
0/15
Latest evidence
30 Sep 2024
3/4/5 13F Highest disclosed value: $38,760,487 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

5AM Venture Management, LLC has the largest disclosed position value at $38.76M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens 5AM Venture Management, LLC's linked filing trail.
Disclosed position value Top 5
Versant Ventures III, LLC $9.39M
Emerald Health Sciences Inc. $3.17M
5AM Venture Management, LLC $38.76M
Versant Venture Management, LLC $7.85M
SPHERA FUNDS MANAGEMENT LTD. $6.11M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Versant Ventures III, LLC
3/4/5
10%+ Owner
—
denominator unverified
$9,386,012
501,925,802 shares
— 18 Aug 2023
Emerald Health Sciences Inc.
3/4/5
10%+ Owner
—
denominator unverified
$3,167,928
169,407,901 shares
— 10 Nov 2022
5AM Venture Management, LLC
13F
Company
13F
—
denominator unverified
$38,760,487
9,913,168 shares
— 30 Sep 2024
Versant Venture Management, LLC
13F
Company
13F
—
denominator unverified
$7,850,123
2,007,704 shares
— 30 Sep 2024
SPHERA FUNDS MANAGEMENT LTD.
13F
Company
13F
—
denominator unverified
$6,113,371
1,563,522 shares
— 30 Sep 2024
BAKER BROS. ADVISORS LP
13F
Company
13F
—
denominator unverified
$5,609,419
1,434,634 shares
— 30 Sep 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
70
Shares
25,208,315
Rows available
70
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q4 2024 vs Q3 2024 Across Filers

Q3 2024 holders
72
Q4 2024 holders
70
Holder diff
-2
Investor Q3 2024 Shares Q4 2024 Shares Share Diff Share Chg % Q3 2024 value Q4 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .